Drug target · GRIN2B
GluN2B
Glutamate ionotropic receptor NMDA type subunit 2B
5 compounds in the CNS pipeline act on GluN2B.
Compounds targeting GluN2B
| Compound | Action | Affinity | Lead program | Developer |
|---|---|---|---|---|
| Apimostinel (GATE-202)primarySmall molecule | PAM | — | Phase 2Major depressive disorder | Syndeio Biosciences, Inc. |
| BI 1569912primarySmall molecule | NAM | — | Phase 2Major depressive disorder | Boehringer Ingelheim |
| NBI-1070770primarySmall molecule | NAM | — | Phase 2Major depressive disorder | Neurocrine Biosciences, Inc. |
| Zelquistinel (GATE-251)primarySmall molecule | PAM | — | Phase 2Major depressive disorder | Syndeio Biosciences, Inc. |
| RapastinelprimarySmall molecule | Partial agonist | — | DiscontinuedMajor depressive disorder | Naurex, Inc. |